Publication: Sıçanlarda travmatik beyin hasarına karşı plazminojen aktivatör inhibitör-1 antagonistinin nöroprotektif etkisinin araştırılması
Abstract
Sıçanlarda Travmatik Beyin Hasarına Karşı Plazminojen Aktivatör İnhibitör-1 Antagonistinin Nöroprotektif Etkisinin Araştırılması Öğrenci adı: Dr. Pınar KURU BEKTAŞOĞLUDanışman adı: Prof. Dr. Hızır KURTELAnabilim dalı: Fizyoloji1.ÖZETAmaç: Plazminojen aktivatör inhibitör-1 (PAI-1) antagonizmasının nöroprotektif olabileceği ileri sürülmektedir. Bu çalışmada travmatik beyin hasarı (TBH) modeli kullanılarak PAI-1 antagonisti uygulamasının olası nöroprotektif etkilerinin incelenmesi amaçlanmıştır.Gereç ve Yöntem: Sprague Dawley erkek sıçanlar, sham (n = 7), TBH (n = 9), TBH + PAI-1 antagonisti (5 ve 10 mg/ kg TM5441 ve TM5484; n = 6-7) gruplarına ayrılmıştır. TBH, ağırlık düşürme modeli ile gerçekleştirilmiş ve sıçanlar 24 saat sonra dekapite edilmiştir. Travma öncesinde ve travma sonrası 24. saatte nörolojik muayene, kuyruk asma, Y labirenti ve obje tanıma testleri yapılmıştır. Travmanın 24. saatinde dekapite edilerek beyin dokularında miyeloperoksidaz, nitrik oksit, luminol ve lusigenin aracılı kemilüminesans düzeyleri ölçülmüştür. ELISA yöntemiyle doku interlökin-1 beta, interlökin-6, tümör nekroz faktör-alfa, interlökin-10, dönüştürücü büyüme faktörü-beta, kaspaz-3, bölünmüş kaspaz-3 ve PAI düzeyleri ölçülmüştür. Hematoksilen-eozin boyama kesitlerinde beyin hasarı incelenmiştir. Bulgular: Travma ile artan miyeloperoksidaz değeri (p < 0,05), 5 ve 10 mg/ kg TM5441 tedavisiyle düşmüştür (p < 0,05-p < 0,01). Kuyruk asma test skorunda travma grubunda artış izlenmiş (p < 0,001), her iki PAI antagonisti ile tüm dozlarda azalma görülmüştür (p < 0,05-0,001). Histolojik hasar skoru travma grubunda korteks, dentat girus ve CA3 bölgelerinde anlamlı artış göstermiş (p < 0,01-0,001), korteks ve dentat girusta tedavi gruplarında azalma izlenmiştir (p < 0,05-0,001). Sonuç: PAI antagonistlerinin TBH sonrası bozulan bazı biyolojik belirteçlere ve davranış testlerine, TM5441 daha ön planda olmak üzere etkili olduğu görülmüştür.
Objectives: Plasminogen activator inhibitor-1 (PAI-1) antagonism is known for its neuroprotective effects. In this study, it was aimed to investigate possible protective effects of PAI-1 antagonist in a rat traumatic brain injury (TBI) model.Materials and Methods: Sprague Dawley male rats were grouped as sham (n = 7), TBI (n = 9), TBI + PAI-1 antagonist (5 and 10 mg/ kg TM5441 and TM5484; n = 6-7). Under anesthesia, TBI was induced by weight-drop model and the rats were decapitated after 24-hour. Before and 24-hour after trauma neurological examination, tail suspension, Y-maze, novel object recognition tests were performed. Activities of myeloperoxidase, nitric oxide levels, luminol- and lucigenin enhanced chemiluminescence were measured. Also, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, interleukin-10, transforming growth factor-beta, caspase-3, cleaved caspase-3, and PAI levels were measured with ELISA method in the brain tissue. Brain injury was graded histopathologically following hematoxylin-eosin staining. Results: Higher levels myeloperoxidase activity in the TBI group (p < 0.05) were found to be suppressed in 5 and 10 mg/ kg TM5441 treatment groups (p < 0.05-p < 0.01). The tail suspension test score was increased in TBI group (p<0.001), and decreased in all treatment groups (p < 0.05-0.001). The histologic damage score was increased statistically significantly in the cortex, dentate gyrus, and CA3 regions in the TBI group (p < 0.01-0.001), decreased in the treatment groups in the cortex and dentate gyrus (p < 0.05-0.001).Conclusion: PAI antagonists, especially TM5441, are effective for some biological markers and behavioral tests after TBI.
Objectives: Plasminogen activator inhibitor-1 (PAI-1) antagonism is known for its neuroprotective effects. In this study, it was aimed to investigate possible protective effects of PAI-1 antagonist in a rat traumatic brain injury (TBI) model.Materials and Methods: Sprague Dawley male rats were grouped as sham (n = 7), TBI (n = 9), TBI + PAI-1 antagonist (5 and 10 mg/ kg TM5441 and TM5484; n = 6-7). Under anesthesia, TBI was induced by weight-drop model and the rats were decapitated after 24-hour. Before and 24-hour after trauma neurological examination, tail suspension, Y-maze, novel object recognition tests were performed. Activities of myeloperoxidase, nitric oxide levels, luminol- and lucigenin enhanced chemiluminescence were measured. Also, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, interleukin-10, transforming growth factor-beta, caspase-3, cleaved caspase-3, and PAI levels were measured with ELISA method in the brain tissue. Brain injury was graded histopathologically following hematoxylin-eosin staining. Results: Higher levels myeloperoxidase activity in the TBI group (p < 0.05) were found to be suppressed in 5 and 10 mg/ kg TM5441 treatment groups (p < 0.05-p < 0.01). The tail suspension test score was increased in TBI group (p<0.001), and decreased in all treatment groups (p < 0.05-0.001). The histologic damage score was increased statistically significantly in the cortex, dentate gyrus, and CA3 regions in the TBI group (p < 0.01-0.001), decreased in the treatment groups in the cortex and dentate gyrus (p < 0.05-0.001).Conclusion: PAI antagonists, especially TM5441, are effective for some biological markers and behavioral tests after TBI.
Description
Keywords
antiinflamatuar, antiinflammatory, antioksidan, antioxidant, Beyin Hasarı, Brain Damage, Fizik tedavi, Health, neuroprotection, nöroproteksiyon, Physical therapy, plasminogen activator inhibitor-1 antagonist, plazminojen aktivatör inhibitör-1 antagonisti, Rehabilitasyon, Rehabilitation, Sağlık, traumatic brain injury, travmatik beyin hasarı
